Stock Analysis

Charles & Colvard, Ltd. Just Beat EPS By 200%: Here's What Analysts Think Will Happen Next

NasdaqCM:CTHR
Source: Shutterstock

A week ago, Charles & Colvard, Ltd. (NASDAQ:CTHR) came out with a strong set of second-quarter numbers that could potentially lead to a re-rate of the stock. The company beat both earnings and revenue forecasts, with revenue of US$12m, some 7.5% above estimates, and statutory earnings per share (EPS) coming in at US$0.09, 200% ahead of expectations. This is an important time for investors, as they can track a company's performance in its report, look at what expert is forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analyst has changed their mind on Charles & Colvard after the latest results.

Check out our latest analysis for Charles & Colvard

earnings-and-revenue-growth
NasdaqCM:CTHR Earnings and Revenue Growth February 6th 2021

Taking into account the latest results, the most recent consensus for Charles & Colvard from sole analyst is for revenues of US$33.6m in 2021 which, if met, would be a decent 8.4% increase on its sales over the past 12 months. Charles & Colvard is also expected to turn profitable, with statutory earnings of US$0.06 per share. Before this earnings report, the analyst had been forecasting revenues of US$33.6m and earnings per share (EPS) of US$0.06 in 2021. The consensus analyst doesn't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

With the analyst reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 80% to US$2.70. It looks as though they previously had some doubts over whether the business would live up to their expectations.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Charles & Colvard's rate of growth is expected to accelerate meaningfully, with the forecast 8.4% revenue growth noticeably faster than its historical growth of 3.4%p.a. over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 10% per year. Charles & Colvard is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analyst reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was also a nice increase in the price target, with the analyst clearly feeling that the intrinsic value of the business is improving.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have analyst estimates for Charles & Colvard going out as far as 2022, and you can see them free on our platform here.

Before you take the next step you should know about the 2 warning signs for Charles & Colvard that we have uncovered.

When trading Charles & Colvard or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About NasdaqCM:CTHR

Charles & Colvard

Operates as a fine jewelry company in the United States and internationally.

Slight with mediocre balance sheet.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor